Tyr172
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr172  -  VAV2 (human)

Site Information
EDGGDDIyEDIIKVE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452202

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 ) , mass spectrometry ( 3 , 4 , 5 ) , mutation of modification site ( 6 ) , phospho-antibody ( 1 , 2 , 6 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 1 ) , breast adenocarcinoma ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , non-small cell lung adenocarcinoma ( 5 ) , neuroblastoma ( 3 , 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PTPRJ (human) ( 2 )
Kinases, in vitro:
EGFR (human) ( 6 )
Treatments:
EGF ( 6 )

Downstream Regulation
Effects of modification on VAV2:
activity, induced ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
cell adhesion, induced ( 2 ) , cell growth, induced ( 1 )
Induce interaction with:
MST3 (human) ( 1 )

References 

1

Cho CY, et al. (2016) MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer. Oncotarget 7, 14586-604
26910843   Curated Info

2

Takahashi K, et al. (2014) CD148 Tyrosine Phosphatase Promotes Cadherin Cell Adhesion. PLoS One 9, e112753
25386896   Curated Info

3

Guo A (2010) CST Curation Set: 10551; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Guo A (2010) CST Curation Set: 10549; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Rikova K (2007) CST Curation Set: 2874; Year: 2007; Biosample/Treatment: cell line, HCC827/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Tamás P, et al. (2003) Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac. J Biol Chem 278, 5163-71
12454019   Curated Info